Trademark Approval

RNS Number : 2381U

Immupharma PLC

13 May 2008

 



For Immediate Release

13 May 2008

ImmuPharma PLC

Lupus drug candidate IPP-201101 obtains trademark LUPUZOR TM 

ImmuPharma PLC (LSE:IMM), ('ImmuPharma' or the 'Company'), the specialist drug discovery and development company, announces today that it received approval of its trademark name LUPUZOR ^TM for its lead drug candidate for Lupus IPP-201101, by the US Patent and Trademark Office.

 

Immupharma has selected the trademark LUPUZOR TM for use in association with its peptide therapy for treating immunological disorders, including systemic lupus erythematosus (SLE). An application for reserving the right to use the LUPUZOR TM trademark was filed, and has now been allowed by the United States Patent and Trademark Office (Serial No. 77239130).

Dimitri Dimitriou, ImmuPharma’s CEO commented: “We believe LUPUZOR ^TM is a milestone in preparing for the commercialisation of our lead drug candidate for Lupus. The LUPUZOR ^TM brand will potentially facilitate the rapid market uptake of the compound by enabling a strong awareness from patients, physicians and healthcare organisations.”

 

LUPUZOR ^TM is currently undergoing a large Phase IIb clinical trial in Lupus patients in Europe and Latin America, results of which are expected later this year. LUPUZOR ^TM has already shown efficacy and safety in a small Phase II study in late 2006. LUPUZOR ^TM may reach the market in around two and a half years’ time, providing substantial revenues for the company.

For further information please contact: 

ImmuPharma PLC:
Dimitri Dimitriou, Chief Executive Officer	[phone]
Dr Robert Zimmer, President & Chief Scientific Officer	+ 33 389 32 76 50
Richard Warr, Chairman	[phone]
Buchanan Communications	+ 44 20 7466 5000
Lisa Baderoon
Rebecca Skye Dietrich
Panmure Gordon & Co
Andrew Burnett	[phone]

For company information, visit www.immupharma.com

 

END

 

 

MSCFKBKQPBKDNPD